Almirall, S.A. (ALM), a global leader in medical dermatology, will participate in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam from September 25 to 28, 2024. This year also marks Almirall’s 80th anniversary, celebrating eight decades of innovation and dedication to improving health and quality of life through its products.
At the EADV Congress, Almirall will present 34 abstracts showcasing the latest research on biologics for moderate-to-severe atopic dermatitis and psoriasis. Highlights include findings on lebrikizumab for atopic dermatitis, tildrakizumab and CAL/BDP cream for plaque psoriasis, and tirbanibulin for actinic keratosis. The company will also host two symposia for experts to discuss advancements in treating these chronic conditions.
Key Presentations
Impact of Psoriasis Treatment on Patient Wellbeing
Almirall will reveal new interim data from the POSITIVE study on tildrakizumab for moderate-to-severe plaque psoriasis at 52 weeks. This study is notable for using the WHO-5 Wellbeing Index as its primary endpoint, assessing health-related psychological wellbeing. Various analyses presented will underscore tildrakizumab’s effectiveness on both skin symptoms and overall wellbeing.
Symposium on Psoriasis Management
The symposium “Advancing Psoriasis Management for Long-Term Patient Outcomes” will feature leading experts such as Prof. Dr. Diamant Thaçi and Prof. Dr. Ulrich Mrowietz. The focus will be on individualized treatment strategies, the latest real-world evidence, and practical approaches for successful psoriasis management, with interactive discussions.
Advancing Atopic Dermatitis Treatment
Almirall will present new data on lebrikizumab, highlighting three years of continuous treatment outcomes. A late-breaking presentation will discuss its effectiveness in patients inadequately controlled by other therapies. The symposium “Precision in AD: How Lebrikizumab is Changing the Treatment Paradigm” will include discussions led by experts like Marjolein Bruin-Weller and Andrew Blauvelt, focusing on lebrikizumab’s clinical impact.
Celebrating 80 Years of Innovation
In 2024, Almirall celebrates 80 years of innovation in medical dermatology, reinforcing its commitment to improving patient lives. With a strong pipeline and a focus on collaboration within the dermatology community, Almirall aims to continue advancing skin science and developing novel treatments for patients worldwide.
